Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Oct 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat fungal keratitis, a serious eye infection that can lead to corneal ulcers and vision problems. Researchers want to find out if using Cyclosporine A eye drops along with the standard treatment, Natamycin, can help improve vision outcomes for patients suffering from this condition. The trial is currently not recruiting participants, but it will focus on adults aged 18 and older who have been diagnosed with fungal keratitis. To be eligible, patients should have a specific level of vision and must be willing to participate in the study.

Participants in this trial can expect to receive careful monitoring and treatment for their condition. It’s important to note that certain factors might exclude someone from joining, such as having other types of eye infections, severe damage to the cornea, or not being able to attend follow-up appointments. The goal of this trial is to find better treatment options that could improve vision for those affected by this challenging eye disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion is based on presenting acuity, not ulcer size.
• • Inclusion of 20/40 = 6/12 = 0.3 Log MAR and 20/400 = 3/60 = +1.3 Log MAR.
• • Smear or culture positive for fungal keratitis, any length.
• • Age 18 years.
• • Willing to participate in study.
• Exclusion Criteria:
• • Co-infection with bacterial or viral keratitis.
• • Corneal perforation.
• • Requiring therapeutic keratoplasty for fungal keratitis.
• • Unwilling or unable to follow up (e.g., living too far from hospital).
• • Presenting acuity better than 20/40 = 6/12 = 0.3 Log MAR or worse than 20/400 = 3/60 = +1.3 Log MAR.
• • Subjects taking cyclosporine at any concentration on presentation.
• • Acuity worse than 20/200 = 6/60 = +1.0 Log MAR in unaffected eye.
• • Pregnant women.
• • Penetrating Keratoplasty.
• • Presents with a 0-7 day history of topical steroid.